Advertisement

Topics

Fewer anti-VEGF injections needed over time

14:00 EDT 17 Aug 2017 | Healio

BOSTON — A real-world look at the treat-and-extend regimen of anti-VEGF agents for treating neovascular age-related macular degeneration showed improved vision in patients with fewer injections per year, according to a poster presented at the American Society of Retina Specialists meeting. Arsh ad M. Khanani, MD, and colleagues presented a retrospective evaluation of the 4-year results of the RENO study, which evaluated the real-world treatment outcomes of intravitreal Lucentis (ranibizumab, Genentech), Eylea (aflibercept, Regeneron) or Avastin (bevacizumab, Genentech) given as-needed for treating wet AMD.

Original Article: Fewer anti-VEGF injections needed over time

NEXT ARTICLE

More From BioPortfolio on "Fewer anti-VEGF injections needed over time"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...